未登录

Y

Yuchang Mao

H指数:7

被引数:162

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In-depth understanding of the structure-based reactive metabolite formation of organic functional groups

DRUG METABOLISM REVIEWS

IF3.8

2025-02-260

PRE

HRA00242-C004, a novel anti-PSMA ADC with high DAR reveals potent in vitro and in vivo anti-tumor efficacy

CANCER RESEARCH

IF16.6

2024-03-221

PRE

HRA00130-C004, a novel anti-DLL3 ADC with bystander effect, high DAR and favorable safety profiles

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor

CANCER RESEARCH

IF16.6

2024-03-221

PRE

Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery

DRUG DISCOVERY TODAY

IF7.5

2023-07-016

PRE

SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles

CANCER RESEARCH

IF16.6

2023-04-1412

PRE

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-05-2019

OAAI

Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2022-04-011

OA

Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2022-02-177

OA

Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2022-01-018

PRE

Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-10-135

PREAI